RB0069

RB0069 is a preclinical-stage therapeutic candidate developed by **Nanjing Regenecore Biotech** (also known as **Nanjing Chongyuan Biotechnology**) for the treatment of **central nervous system (CNS) diseases**. The program is part of the company's pipeline focused on neuroregeneration and the development of therapies for neurological disorders. As of 2024, specific details regarding the drug's molecular target, mechanism of action, and modality (e.g., small molecule or biologic) remain proprietary and have not been publicly disclosed. The asset is currently undergoing preclinical evaluation to support potential future clinical development.